Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Growth in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 241,700 shares, an increase of 536.1% from the November 30th total of 38,000 shares. Based on an average trading volume of 313,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 16.6% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Roth Mkm dropped their price objective on Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating on the stock in a research note on Monday, September 23rd. StockNews.com began coverage on shares of Aptevo Therapeutics in a research note on Monday, December 9th. They issued a “sell” rating for the company.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Stock Up 5.6 %

NASDAQ:APVO traded up $0.27 during trading on Thursday, reaching $5.11. The company’s stock had a trading volume of 151,604 shares, compared to its average volume of 134,010. Aptevo Therapeutics has a 12 month low of $3.65 and a 12 month high of $399.60. The firm has a 50 day moving average of $252.13 and a 200-day moving average of $412.75.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.